Cas:109-23-9 N-[(octadecanoylamino)methyl]octadecanamide manufacturer & supplier

Chemical Name:N-[(octadecanoylamino)methyl]octadecanamide

CAS.NO:109-23-9

Synonyms:Methylenebisstearoamide;N,N’-Methylenebisstearic acid amide;Methylenebis(stearamide);Bis Amide;N,N’-Methylenestearamide;Methylenedistearamide;N,N’-Methylenedistearamide;Armowax;N,N’-Methylen-bis-octadecansaeureamid;methylene-bis-stearic acid amide;Octadecanamide,N,N’-methylenebis;bis-stearoylamino-methane;N,N’-Methylen-bis-stearylamid;EINECS 203-657-3

Molecular Formula:C₃₇H₇₄N₂O₂

Molecular Weight:578.99600

HS Code:2924199090

Physical and Chemical Properties:

Melting point:148-150ºC

Boiling point:706.8ºC at 760mmHg

Density:0.889g/cm3

Index of Refraction:1.475

PSA:58.20000

Exact Mass:578.57500

LogP:12.48110

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Methylenebisstearoamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 203-657-3 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,bis-stearoylamino-methane Use and application,N,N’-Methylenestearamide technical grade,usp/ep/jp grade.

Related News: Advanced intermediate suppliers not only have strong bargaining power for junior suppliers, but more importantly, because they undertake the production of advanced intermediates with high technical content and maintain closer ties with multinational companies, raw materials Price fluctuations have little effect on it. N-[(octadecanoylamino)methyl]octadecanamide manufacturer Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely. N-[(octadecanoylamino)methyl]octadecanamide supplier It is foreseeable that in the future, the capacity and output of bulk APIs in China will decrease, the supply-demand relationship will be balanced, and prices and profits will gradually return to a more reasonable range. The era of low prices in the past will be gone forever. Individual APIs Varieties may even lose their price competitive advantage and move abroad. N-[(octadecanoylamino)methyl]octadecanamide vendor The Company��s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). N-[(octadecanoylamino)methyl]octadecanamide factory In 2016, the export volume of China’s specialty drug substances reached US $ 3.53 billion, accounting for 13.8% of the total drug substances.